Diabetic ketoacidosis
11 results
1 - 11Type 1 diabetes in fair to good control not associated with reduced school performance in children
Low-dose insulin at least as good as standard doses in biochemical control of kids with DKA
No benefit from screening for asymptomatic CAD in type 2 diabetes
Sotagliflozin reduces hospitalizations and urgent visits for heart failure, but has no mortality benefit (SCORED)
Insulin pumps lower A1C more than multiple insulin doses in patients with type 2 DM (OpT2mise)
SGLT2 inhibitors = little effect on glycemic control or all-cause mortality, but decrease CV deaths in older adults with T2DM plus heart failure
Limited meta-analysis suggests SGLT2 inhibitors improve cardiovascular outcomes in patients with T2DM + atherosclerosis
Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58)
Limited SR demonstrates SGLT2 inhibitors improve outcomes in adults with heart failure